Skip to content

This site is intended for healthcare professionals in the UK only. Prescribing information and adverse event reporting can be found in the footer.

  • Why Nevolat
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • The ideal Nevolat patient
  • How to Administer
    • Dose Titration
    • Method of administration
    • Storage and shelf life
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs
  • Why Nevolat
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • The ideal Nevolat patient
  • How to Administer
    • Dose Titration
    • Method of administration
    • Storage and shelf life
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs

Frequently asked questions about Nevolat®

Two Nevolat packages side by side

What should I ask my patient before prescribing Nevolat®?

As well as assessing your patient’s BMI and comorbidities to ensure they are eligible for Nevolat® it is important to establish whether they have or had any problems with their pancreas, kidneys or liver.1 Are there any other contraindicated medical problems, such as gastroparesis or problems with digesting food? Are they pregnant, breastfeeding or planning to become pregnant?1

Check the patient’s current prescriptions, including over-the-counter medicines, medicines to treat diabetes, insulin, sulfonylureas, vitamins and herbal supplements.1

How should I guide my patient to use Nevolat®?

A member of the healthcare team, GP or nurse practitioner should try and demonstrate injection of Nevolat® using the pre-filled pen on the patient, the first time it is administered. The Method of Administration section of this website provides step-by-step instructions.

What key points of using Nevolat® should I ensure I mention to my patient?

  • Refer your patient to the step-by-step instructions on the Patient Information Leaflet, as well as those on the Nevolat® patient site.1
  • Remind patients they need to inject under the skin of their stomach, thigh or upper arm and never into a muscle or vein.1
  • They should rotate the injection site each time to minimise the risk of lumps from cutaneous amyloidosis.
  • Insulin and Nevolat® should not be mixed together in the same injection. The same body area for both can be used (for example their abdomen) but they should not administer the injections right next to each other.2
  • Emphasise the need to avoid needle sharing to prevent cross contamination or infection.1

With respect to side effects, what should I mention?

Possible anaphylaxis

It is worth making the patient aware that a few cases of anaphylactic reactions have been seen with liraglutide. Establish whether they are hypersensitive to any of the excipients of the liraglutide pen (sodium citrate dihydrate, propylene glycol, phenol, hydrochloric acid (for pH adjustment) and sodium hydroxide (for pH adjustment) in water. Make patients aware of the symptoms of an anaphylactic reaction, such as hypotension, palpitations, breathlessness (dyspnoea) and swelling (oedema) which have been reported with marketed use of liraglutide. If the patient suspects they are having an anaphylactic reaction, they should contact 999 immediately and follow the steps below. Discontinue liraglutide and do not restart treatment.1,2,3

  1. Use an adrenaline auto-injector (such as an EpiPen) if you have one – instructions should be included on the side of the injector.
  2. Call 999 for an ambulance and say that you think you’re having an anaphylactic reaction.
  3. Lie down – you can raise your legs, and if you’re struggling to breathe, raise your shoulders or sit up slowly (if you’re pregnant, lie on your left side).
  4. If your symptoms have not improved after 5 minutes, use a 2nd adrenaline auto-injector.
  5. Do not stand or walk at any time, even if you feel better.

 

Common side effects (1 in 10 people): gastrointestinal1

Refer your patient to the Patient Information Leaflet, as well as the safety and tolerability section of the patient site. Mention that the most common side effects of using Nevolat® may include nausea, diarrhoea, vomiting, decreased appetite, indigestion and constipation. Patients should ensure they are well hydrated when taking Nevolat®to avoid dehydration and combat the effects of vomiting or diarrhoea if they experience them. Reassure them that these side effects are common (around 1 in 10 people) and should disappear over time. If they continue to experience them after two weeks to a concerning level, they should contact their healthcare professional.1,2

 

Hypoglycaemia (1 in 10 people):1

Flag the warning signs of low blood sugar to your patient. If they experience sudden onset of cold sweat, cool pale skin, headache, fast heartbeat, feeling sick, feeling very hungry, changes in vision, feeling sleepy, feeling weak, nervous, anxious, confused, difficulty concentrating or shaking (tremor) they should contact their healthcare professional.1 If the patient’s blood sugar level is below 4mmol/L they should eat or drink something that will raise their blood sugar quickly, such as a sugary fizzy drink or a glass of fruit juice, 5 glucose or dextrose tablets, a small handful of sweets or 2 tubes of glucose gel. They should then check their blood sugar after 10 to 15 minutes and repeat the sugary snack if their blood glucose remains below 4mmol/L. After a further 10 to 15 minutes, they should again check their blood sugar levels. Once their blood sugar is above 4mmol/L then are advised to eat something more substantial that will keep their blood sugar up for longer such as some biscuits or a sandwich or their next meal if it is due.3

Man running on a treadmill in a gym

 

 

 

 

  1. Nevolat® (liraglutide) Patient Information Leaflet. Available from https://www.ema.europe.eu/en/documents/product-information/nevolat-epa: product-information_en.pdf. Accessed December 2024.
  2. Nevolat® (liraglutide) Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/100226/smpc. Accessed December 2024.
  3. NHS website; Low blood sugar (hypoglycaemia), How to treat low blood sugar yourself. Available from https://www.nhs.uk/conditions/low-blood-sugar-hypoglycaemia/. Accessed December 2024.
  4. NHS Health A to Z, Anaphylaxis. Available from: https://www.nhs.uk/conditions/anaphylaxis/. Accessed December 2024

000697597 | December 2024

Prescribing information can be found here.

  • Navigation
    • Terms of Use
    • HCP Privacy
    • Cookies Policy
    • GDPR

MORE ABOUT US

linkedin

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Zentiva via email to UKMedInfo@zentiva.com
or via phone on 0800 090 2408.

Copyright Zentiva Group, a.s. © 2025

I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the gateway page after clicking on No.

No, I am not Yes, I am